Puma Biotechnology Commences the P-II (ALISCA-Breast1) Study of Alisertib in HR-Positive, HER2-Negative Metastatic Breast Cancer
Shots: The company has commenced P-II (
Endeavor BioMedicines Reports the First Patient Dosing Under P-IIb (WHISTLE-PF) Study of Taladegib (ENV-101) to Treat Idiopathic P...
Shots: Endeavor BioMedicines has dosed the first patient in its P-IIb (
Novo Nordisk Highlights the Part 1 Results from P-III (ESSENCE) Study of Semaglutide to Treat MASH at AASLD 2024 - The Liver Meeti...
Shots: The P-III (ESSENCE) study assessed semaglutide (2.4mg, QW) vs PBO in MASH a...
Eli Lilly Reports the Data from P-II Trial of Muvalaplin in Adults with High Risk for Cardiovascular Events
Shots: Eli Lilly's P-II clinical evaluation of muvalaplin (10mg, 60mg & 24...
